• Home
  • News

Sichenzia Ross Ference Carmel LLP Represents Beyond Air in $16.0 Million Registered Direct Offering

beyond air logo

Press Release – New York, NY – March 22, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Beyond Air, Inc. (NASDAQ: “XAIR”), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, in a securities purchase agreement whereby the investors have agreed to purchase 9,638,556 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,638,556 shares of common stock at a purchase price of $1.66 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. 

Roth Capital Partners and Laidlaw & Company (UK) Ltd. acted as co-placement agents for the offering.

The securities in the offering described above are being offered by the Company pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-262311) previously filed with the U.S. Securities and Exchange Commission (the “SEC”), which was declared effective on February 1, 2022

The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia and Avital Perlman and associate Soumya Cheedi.